Praxis Precision Medicines (PRAX) Fundamentals 2026 — Revenue Analysis | SniperIQ
Praxis Precision Medicines (PRAX) is a US-listed Healthcare company in Biotechnology with a market capitalization of $6.5B, trading at
Praxis Precision Medicines (PRAX) has a market capitalization of approximately $6.5B, trading at
Praxis Precision Medicines's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 6.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Praxis Precision Medicines runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Praxis Precision Medicines does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Praxis Precision Medicines carries a debt-to-equity ratio of 0.00x and a current ratio of 15.88x, with a market beta of 2.76. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Praxis Precision Medicines (PRAX) the key facts are: market cap $6.5B, 52-week range 37.19-366.52. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Get Praxis Precision Medicines's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.